Archived explainer. For the current picture see today's CDNA page.
CAREDX INC (CDNA) is up +35.60% in the latest session. Our newswire has captured 6 stories on CDNA across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
CareDx Inc. (CDNA) surged 35.60% to $40.34 in the latest session, driven by the finalization of Medicare coverage for its molecular transplant surveillance tests. The policy change, which grants reimbursement for kidney, heart, and lung transplant monitoring, has bolstered investor confidence and triggered a sharp rally in the stock. The move comes after a period of volatility and sets the stage for broader adoption of CareDx's services.
The stock’s sharp rise follows the confirmation of a finalized Medicare Local Coverage Determination (LCD) for CareDx’s molecular testing. This policy shift ensures coverage for up to six tests in the first year and four annually in the following two years for kidney rejection surveillance. The final policy is expected to take effect on August 30. The news has been interpreted as a key validation of CareDx’s market position and a catalyst for future revenue growth. The stock had already seen an 18% jump earlier in the session, with the day’s move marking a significant reversal from recent underperformance.
The stock’s 52-week range is $10.96 to $30.00, meaning the current price is well above its previous high. The session’s volume was unusually high, though specific figures were not provided. Recent insider transactions show six sales totaling $2.7 million over the last 90 days, with no insider purchases recorded. Despite the stock’s strong performance, CareDx remains unprofitable, with a trailing twelve-month net margin of -2.0% and an EPS of -0.16. The company’s revenue has grown 19.2% in the same period.
Investors will now look to CareDx’s second quarter 2026 financial results, scheduled for release on July 30. The earnings report will be followed by a webcast and conference call, offering further insight into the company’s financial health and the potential impact of the new Medicare coverage.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
CareDx, Inc. will reveal its second quarter 2026 financial results on July 30, drawing investor attention after a sharp 23.9% move in the stock. The article unpacks what the pre-announcement means for market sentiment, outlines key event information, and explores the broader significance for precision medicine investors.
CareDx shares surged after Medicare finalized coverage for its molecular transplant surveillance tests, confirming reimbursement across kidney, heart and lung transplant monitoring services.
CareDx (CDNA) stock jumps 18% after Medicare finalizes LCD coverage for transplant molecular tests.
The finalized Medicare Local Coverage Determination (LCD) grants comprehensive coverage for CareDx’s leading molecular surveillance tests in kidney, heart, and lung transplants, offering increased clarity and stability for patients and providers. This article examines the core coverage changes, how they align with clinical needs, and what they could mean for CareDx's future.
Results will be released after market close, followed by a 1:30 p.m. PT webcast and conference call; CareDx will provide live and archived access online.
Kidney rejection-surveillance coverage allows up to six tests in year one and four annually in years two and three; the final policy is expected to take effect Aug. 30.
More on CDNA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CDNA move explainers: 2026-07-17 · 2026-07-16